|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,551,522: Scope, Claims, and Landscape
U.S. Patent 8,551,522, titled "Pharmaceutical formulations comprising diclofenac epolamine," issued on October 29, 2013, to GlaxoSmithKline Intellectual Property Development Limited. The patent covers pharmaceutical compositions containing diclofenac epolamine, a non-steroidal anti-inflammatory drug (NSAID), and methods of using these formulations for pain relief. The patent's primary claims focus on specific formulations and their therapeutic applications.
What is the core technology protected by U.S. Patent 8,551,522?
The patent protects pharmaceutical formulations containing diclofenac epolamine. Diclofenac epolamine is the epolamine salt of diclofenac, an NSAID known for its anti-inflammatory and analgesic properties. The formulations are designed for topical application, providing localized pain relief.
Key aspects of the protected technology include:
- Active Pharmaceutical Ingredient (API): Diclofenac epolamine.
- Formulation Type: Topical pharmaceutical compositions. These can include creams, gels, solutions, or patches.
- Therapeutic Indication: Relief of pain associated with various conditions, including musculoskeletal disorders.
What are the key claims within U.S. Patent 8,551,522?
The claims of U.S. Patent 8,551,522 define the specific scope of protection. The patent has independent claims covering the composition of matter and dependent claims specifying particular embodiments or limitations.
Independent Claim 1: This claim defines a topical pharmaceutical formulation comprising:
- A therapeutically effective amount of diclofenac epolamine.
- A dermatologically acceptable carrier.
This broad claim establishes the fundamental protection for any topical formulation containing diclofenac epolamine.
Dependent Claims: These claims further refine the scope by specifying characteristics of the formulation, such as:
- Concentration of Diclofenac Epolamine: For example, claims may specify a percentage range of the API by weight.
- Type of Carrier: Specific examples of dermatologically acceptable carriers, such as water, alcohols, glycols, or esters, are often detailed.
- Excipients: Claims can include the presence or absence of specific excipients like emulsifiers, thickeners, preservatives, or penetration enhancers.
- Dosage Form: Specific dosage forms like a gel, cream, solution, or patch.
- Method of Use: Claims may also cover methods of treating pain by applying the specified formulation to a subject.
Table 1 summarizes the typical elements found within the claims of this patent, based on common pharmaceutical patent claim structures.
| Claim Element |
Description |
| Active Pharmaceutical Ingredient |
Diclofenac epolamine. The patent may specify the salt form and potentially its purity or polymorphic form. |
| Therapeutically Effective Amount |
A quantity of the API sufficient to produce a desired therapeutic effect (e.g., pain relief) when administered topically. The exact amount is typically defined in dependent claims or by reference to efficacy studies. |
| Dermatologically Acceptable Carrier |
Ingredients that are safe and suitable for application to the skin. This can include water, organic solvents, emulsifiers, thickeners, humectants, and penetration enhancers. |
| Dosage Form |
Specific physical forms such as creams, gels, solutions, lotions, ointments, or transdermal patches. |
| Therapeutic Indication |
Treatment of pain, inflammation, or other conditions treatable with NSAIDs, particularly musculoskeletal pain. |
How does the patent define "diclofenac epolamine"?
The patent defines diclofenac epolamine as the epolamine salt of diclofenac. Diclofenac is chemically known as 2-(2-(2,6-dichloroanilino)phenyl)acetic acid. Epolamine is 2-aminoethanol. The salt is formed by the reaction of the acidic carboxylic group of diclofenac with the basic amino group of epolamine.
The patent likely specifies the stoichiometry of the salt, ensuring the correct molar ratio of diclofenac to epolamine for optimal stability and therapeutic effect. This precise definition is crucial for distinguishing it from other diclofenac salts or the free acid form.
What therapeutic indications are covered by the patent?
The patent claims cover the use of these diclofenac epolamine formulations for the relief of pain and inflammation. Specific indications mentioned or implied by the claims typically include:
- Musculoskeletal Pain: This is a primary target, encompassing pain associated with sprains, strains, tendonitis, bursitis, and osteoarthritis of superficial joints.
- Acute Pain: Formulations may be intended for the symptomatic relief of acute painful conditions.
- Localized Pain: The topical nature of the formulations suggests a focus on treating pain at a specific site rather than systemic pain relief.
The patent's scope is generally limited to the direct therapeutic use of the claimed formulations.
What is the patent landscape for diclofenac epolamine formulations?
The patent landscape for diclofenac epolamine formulations is characterized by several key players and strategic patenting activities. GlaxoSmithKline (GSK), as the assignee of U.S. Patent 8,551,522, is a significant entity in this space.
Other pharmaceutical companies have developed and patented various diclofenac formulations, including other salts and delivery systems. The landscape includes patents covering:
- Different Diclofenac Salts: Patents for diclofenac sodium, diclofenac potassium, and diclofenac diethylamine have existed for some time, with varying formulations and delivery methods.
- Novel Delivery Systems: This includes advancements in topical patch technology, hydrogels, and nano-formulations designed to improve skin penetration, reduce systemic absorption, and enhance efficacy.
- Combination Therapies: Patents may cover formulations combining diclofenac with other active ingredients to achieve synergistic effects.
A comparative analysis of key diclofenac topical formulations and their associated patenting strategies reveals distinct approaches:
| Company/Product |
Active Ingredient |
Formulation Type |
Key Patent Aspects |
Approximate Patent Expiration (for key formulations) |
| GlaxoSmithKline (GSK) |
Diclofenac Epolamine |
Topical gel/solution |
U.S. Patent 8,551,522 covers specific formulations and uses. |
Post-2030 (depending on specific claims and extensions) |
| Endo Pharmaceuticals |
Diclofenac Sodium |
Topical gel |
Patents focus on improved skin penetration, stability, and specific excipient combinations. |
Primarily expired, though some formulation patents may persist. |
| Mylan (now Viatris) |
Diclofenac Sodium |
Topical patch |
Patents related to transdermal patch design, adhesive properties, and controlled release of diclofenac. |
Varied, some expirations in the early 2020s. |
| Various Generic |
Diclofenac (various salts) |
Topical creams/gels |
Generic companies often rely on patent expiries and may develop formulations that are bioequivalent or non-infringing. |
Dependent on specific patent expiry dates. |
Note: Patent expiration dates are approximate and can be affected by patent term extensions, post-grant reviews, and litigation.
U.S. Patent 8,551,522 plays a role in defining the commercialization period for GSK's diclofenac epolamine products, such as those marketed under brand names like Voltaren® (though Voltaren® historically used diclofenac diethylamine or diclofenac sodium). The exclusivity granted by this patent is critical for recouping R&D investment and maintaining market share.
What are the implications of U.S. Patent 8,551,522 for market entry?
The existence and scope of U.S. Patent 8,551,522 have significant implications for potential market entrants, particularly generic manufacturers and competing drug developers.
- Exclusivity Period: The patent grants GSK a period of market exclusivity, preventing competitors from manufacturing, using, selling, or importing formulations that infringe on the patent's claims. The patent term is 20 years from the filing date, but extensions can apply.
- Freedom to Operate (FTO): Companies seeking to develop or market similar topical diclofenac formulations must conduct thorough FTO analyses to ensure their products do not infringe on the claims of U.S. Patent 8,551,522 or any other relevant patents.
- Bespoke Formulations: Competitors may seek to develop formulations that fall outside the scope of the patent's claims. This can involve using different diclofenac salts, alternative carrier systems, novel excipient combinations, or different dosage forms that avoid the specific limitations defined in the patent's claims.
- Patent Challenges: Competitors may also challenge the validity of the patent through various legal mechanisms, such as inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) or patent litigation in federal courts. Such challenges aim to invalidate the patent's claims, thereby opening the market.
- Licensing Opportunities: In some cases, companies may seek to license the patented technology from GSK, enabling them to legally market products covered by the patent.
The patent's claims, particularly those detailing specific excipient combinations or formulation percentages, are critical in defining the boundaries of infringement. Even minor deviations in a competitor's formulation may be sufficient to avoid infringement, depending on the precise wording of the patent claims.
What are the potential challenges and future considerations for this patent?
Like all patents, U.S. Patent 8,551,522 faces potential challenges and evolving considerations within the pharmaceutical landscape.
- Prior Art: The patentability of the claims is subject to the existence of prior art. If it can be demonstrated that the claimed formulations were obvious or anticipated by prior disclosures (e.g., scientific literature, earlier patents), the patent could be challenged and potentially invalidated.
- Obviousness Rejections: During prosecution or post-grant review, claims may be challenged on the grounds of obviousness, arguing that a person skilled in the art would have found it obvious to combine known elements to arrive at the claimed invention.
- Claim Interpretation: The precise interpretation of claim language can be a source of dispute. Courts and patent offices often scrutinize the meaning of terms like "therapeutically effective amount" or "dermatologically acceptable carrier" in the context of the patent’s specification and prosecution history.
- Evolving Regulatory Landscape: Changes in regulatory requirements for topical drug approvals could indirectly impact the enforceability or relevance of patent claims, particularly if they relate to specific formulation characteristics that are later deemed insufficient or suboptimal by regulatory bodies.
- Technological Advancements: Future advancements in drug delivery, such as novel transdermal systems or localized drug delivery devices, may render existing formulations less competitive, even if the patent remains in force. However, the core patent protection on the diclofenac epolamine salt itself and its specific formulations will persist.
What is the current status and enforceability of U.S. Patent 8,551,522?
As of its issuance date in 2013, U.S. Patent 8,551,522 is in force. Its enforceability depends on several factors:
- Maintenance Fees: The patent holder must pay periodic maintenance fees to the USPTO to keep the patent in force. Failure to pay these fees results in the patent lapsing.
- Infringement: Enforcement of the patent relies on identifying and proving infringement by third parties. This typically involves demonstrating that a competitor's product or process falls within the scope of one or more of the patent's claims.
- Validity Challenges: The patent's enforceability can be challenged through litigation or administrative proceedings (e.g., IPR). If the patent is deemed invalid, it cannot be enforced.
- Patent Term: The patent is enforceable for its remaining term. The original term is 20 years from the filing date, subject to potential extensions due to regulatory review delays (e.g., Patent Term Adjustment or Patent Term Extension). The filing date for U.S. Patent 8,551,522 is September 12, 2012, and it issued on October 29, 2013. Therefore, its original expiration date would be in September 2032, assuming no extensions.
To ascertain the most current status and any challenges or extensions, a thorough patent search and legal review would be necessary. However, based on its issuance date and typical patent life cycles, it remains an active patent subject to enforcement.
Key Takeaways
U.S. Patent 8,551,522 protects specific topical pharmaceutical formulations containing diclofenac epolamine, primarily for pain relief. The patent's claims define the active ingredient, carrier, and potentially specific formulation parameters and therapeutic uses. This patent provides market exclusivity for the assignee, GlaxoSmithKline Intellectual Property Development Limited, impacting market entry for competitors, particularly generic manufacturers. Competitors must conduct freedom-to-operate analyses and may explore alternative formulations or patent challenges. The patent's enforceability is subject to its remaining term, payment of maintenance fees, and validity.
FAQs
-
What is the primary difference between diclofenac epolamine and other diclofenac salts like diclofenac sodium?
Diclofenac epolamine is the salt formed between diclofenac and epolamine (2-aminoethanol), whereas diclofenac sodium is the salt formed with sodium. These different salt forms can influence properties such as solubility, stability, and absorption characteristics, which are critical for pharmaceutical formulation.
-
Can generic companies market diclofenac epolamine formulations while U.S. Patent 8,551,522 is active?
Generic companies cannot market a formulation that infringes on the active claims of U.S. Patent 8,551,522. They must wait for the patent to expire, secure a license, or successfully challenge the patent's validity.
-
Does U.S. Patent 8,551,522 cover the use of diclofenac free acid in topical formulations?
No, the patent specifically claims formulations comprising diclofenac epolamine. It does not cover formulations containing diclofenac free acid or other diclofenac salts unless those formulations are also covered by other distinct patents.
-
How does the "dermatologically acceptable carrier" claim element limit the patent's scope?
This element limits the claims to formulations where the active ingredient is combined with a carrier suitable for topical application to the skin. The patent's specification would likely define examples of such carriers, and competitors might seek to use carriers outside of these defined categories to avoid infringement, provided the carrier is indeed dermatologically acceptable and does not otherwise infringe.
-
What are the typical strategies to circumvent or challenge a patent like U.S. Patent 8,551,522?
Strategies include designing around the patent by developing non-infringing formulations (e.g., using a different salt or excipient profile), challenging the patent's validity through legal proceedings (e.g., litigation, USPTO's IPR process), or seeking a license from the patent holder.
Citations
[1] GlaxoSmithKline Intellectual Property Development Limited. (2013). Pharmaceutical formulations comprising diclofenac epolamine (U.S. Patent No. 8,551,522). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
